EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Teleangiectatic Osteosarcoma Treated by Surgery and Chemotherapy: A Report of 223 Affected Patients From the Cooperative Osteosarcoma Study Group ( COSS )

Stefan S Bielack iD, Vanessa Mettmann iD, Daniel Baumhoer iD, Andreas Beilken iD, Claudia Blattmann iD, Godehard Friedel iD, Jendrik Hardes iD, Wolf Hassenpflug iD, Leo Kager iD, Matthias Kevric, Thekla von Kalle iD, Andreas Kulozik iD und 6 weitere

Cancer Medicine · 2025

DOI: 10.1002/cam4.71211 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, 2025. Verfasst von Stefan S Bielack und 17 weiteren Autor:innen. Beteiligte Einrichtung: Pädiatrie 5 (Onkologie, Hämatologie, Immunologie), Stuttgart Cancer Center, Zentrum für Kinder-, Jugend- und Frauenmedizin, Klinikum Stuttgart - Olga…. Hauptthemen laut MEDLINE: Osteosarcoma, Bone Neoplasms. Die Arbeit nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Förderkreis Krebskranke Kinder e.V. Stuttgart.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Teleangiectatic osteosarcoma is a histologic subtype of osteosarcoma that can mimic aneurysmal bone cysts and has so far been incompletely characterized. Patients and Methods We used the database of the Cooperative Osteosarcoma Study Group COSS (patient‐registration 1980–2019) to better understand this rare histologic variant.

Results

223 eligible patients were identified, 164 having reference pathology (median age 15.9 (3.7–69.7) years; male 134, female 89; tumor sites limb 208 (201 metaphyses, 66 pathologic fractures), trunk 13, head & neck 2; 26 with primary metastases). Known tumor‐predisposition syndromes were rare. Therapy included surgery in 215, radiotherapy in 10, and chemotherapy in all patients. Tumor response to preoperative treatment was good in 71% of 165 cases with available data. After a median follow‐up of 7.1 (0.2–32.1) years for all patients and 10.5 (0.2–32.1) years for 152 survivors, 5‐/10‐year actuarial event‐free and overall survival expectancies were 61%/57% and 73%/66%, respectively. Five unrelated malignancies occurred during this period. The presence of primary metastases, pathologic fracture, poor response to neoadjuvant chemotherapy, and not obtaining a complete macroscopic remission were associated with inferior outcomes for both event‐free and overall survival ( p < 0.01).

Discussion

This large analysis proves teleangiectatic osteosarcoma to be a disease predominantly of the metaphyses of the young. While detected only rarely, the true incidence of genetic tumor predispositions would require prospective assessments. Behaving like other osteosarcoma subtypes in many other ways, this variant may show greater chemosensitivity and hence somewhat better outcomes than other subtypes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OsteosarcomaBone NeoplasmsHumansMaleFemaleAdolescentAdultYoung AdultMiddle AgedChildAgedChild, PreschoolTreatment OutcomeCombined Modality Therapy

Stichwörter der Autor:innen

chemotherapydemographicsosteosarcomaoutcomessurgeryteleangiectatic

Autor:innen und Institutionen

  • Pädiatrie 5 (Onkologie, Hämatologie, Immunologie), Stuttgart Cancer Center, Zentrum für Kinder-, Jugend- und Frauenmedizin, Klinikum Stuttgart - Olgahospital, Stuttgart, Germany.
  • Klinik für Kinder- und Jugendmedizin, Pädiatrische Hämatologie und Onkologie, Universitätsklinikum Münster, Münster, Germany.
  • Klinik für Kinder- und Jugendmedizin - Hämatologie und Onkologie, Universitätsmedizin Mannheim, Mannheim, Germany.
  • Knochentumor- Referenzzentrum, Institut für Medizinische Genetik und Pathologie, Universitätsspital Beider Basel, und Basel Research Centre for Child Health, Basel, Switzerland.
  • Kinder- und Jugendklinik, Städtisches Klinikum Braunschweig gGmbH, Braunschweig, Germany.
  • Klinik für Pädiatrische Hämatologie und Onkologie, Medizinische Hochschule Hannover, Hannover, Germany.

ORCID-Profile: Stefan S Bielack, Vanessa Mettmann, Daniel Baumhoer, Andreas Beilken, Claudia Blattmann, Godehard Friedel, Jendrik Hardes, Wolf Hassenpflug, Leo Kager, Thekla von Kalle, Andreas Kulozik, Markus Metzler, Michaela Nathrath, Claudia Rossig, Mathias Werner, Stefanie Hecker-Nolting

Förderung

  • Förderkreis Krebskranke Kinder e.V. Stuttgart

Zitieren

APA

Bielack, S. S., Mettmann, V., Baumhoer, D., Beilken, A., Blattmann, C., Friedel, G., Hardes, J., Hassenpflug, W., Kager, L., Kevric, M., von Kalle, T., Kulozik, A., Metzler, M., Nathrath, M., Rossig, C., Sorg, B., Werner, M., & Hecker-Nolting, S. (2025). Teleangiectatic Osteosarcoma Treated by Surgery and Chemotherapy: A Report of 223 Affected Patients From the Cooperative Osteosarcoma Study Group ( COSS ). Cancer Medicine. https://doi.org/10.1002/cam4.71211

Vancouver

Bielack SS, Mettmann V, Baumhoer D, Beilken A, Blattmann C, Friedel G, et al. Teleangiectatic Osteosarcoma Treated by Surgery and Chemotherapy: A Report of 223 Affected Patients From the Cooperative Osteosarcoma Study Group ( COSS ). Cancer Medicine. 2025. doi:10.1002/cam4.71211

BibTeX
@article{Bielack2025,
  author = {Bielack, Stefan S and Mettmann, Vanessa and Baumhoer, Daniel and Beilken, Andreas and Blattmann, Claudia and Friedel, Godehard and Hardes, Jendrik and Hassenpflug, Wolf and Kager, Leo and Kevric, Matthias and von Kalle, Thekla and Kulozik, Andreas and Metzler, Markus and Nathrath, Michaela and Rossig, Claudia and Sorg, Benjamin and Werner, Mathias and Hecker-Nolting, Stefanie},
  title = {Teleangiectatic Osteosarcoma Treated by Surgery and Chemotherapy: A Report of 223 Affected Patients From the Cooperative Osteosarcoma Study Group ( COSS )},
  journal = {Cancer Medicine},
  year = {2025},
  doi = {10.1002/cam4.71211}
}
Kostenlos starten →